BMO Capital analyst Kostas Biliouris maintained a Buy rating on Korro Bio yesterday and set a price target of $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Korro Bio’s lead program, KRRO-110. The completion of dosing in healthy volunteers without any significant adverse events has derisked the safety profile of KRRO-110, which is crucial for its therapeutic application in treating Alpha-1 Antitrypsin Deficiency (AATD). The anticipated data from KRRO-101 in the second half of the year is expected to show superior efficacy compared to existing investigational therapies, potentially driving significant upside in the stock.
Moreover, the company’s strong cash position is expected to support the completion of ongoing clinical trials and further development of its pipeline, including promising programs targeting metabolic disorders and cardiometabolic conditions. The RNA editing technology employed by Korro Bio, coupled with the high unmet need and lack of approved disease-modifying therapies for AATD, positions KRRO-110 as a significant commercial opportunity. These factors, along with the potential for additional non-dilutive capital from partnered programs, contribute to the Buy rating.
Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Centessa Pharmaceuticals. According to TipRanks, Biliouris has an average return of -7.5% and a 37.35% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $90.00 price target.